NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

INmune Bio Inc. (INMB) Stock Analysis

INmune Bio Inc. (INMB) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

INMB

$2.44

+$0.17 (+7.49%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare INMB with… →

INMB Key Statistics

As of Sep 4, 2026
Trading
Open
$2.27
Previous Close
$2.27
Day's Range
2.22–2.45
52-Week Range
1.09–2.50
Volume
316.40K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.94
Valuation
Market Cap
$67.72M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.62
Financials (FY)
Revenue (FY)
$50.00K+257.14%
Net Income (FY)
−$45.93M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
27.75M
1-Year Return
+27.08%
Dividend and dates
Earnings Date
October 29, 2026
Avg Volume
710.74K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

INMB Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+56.41%
2025−66.60%
2024−58.53%
2023+77.60%
2022−37.84%
2021−40.77%
2020+196.90%
2019 (partial year)−27.41%

As of September 4, 2026.

INMB Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$50.00K−$45.93M−91866.0%
2024$14.00K−$42.08M−300585.7%
2023$155.00K−$30.01M−19360.0%
2022$374.00K−$27.30M−7299.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$50.00K—−$30.87M−$45.93M−91866.0%
2024$14.00K—−$42.64M−$42.08M−300585.7%
2023$155.00K—−$29.74M−$30.01M−19360.0%
2022$374.00K—−$25.95M−$27.30M−7299.2%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

INMB Valuation vs Biotechnology Median

Median of 656 stocks
MetricINMBBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 10 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values INmune Bio Inc. (INMB) at $67.72M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 21 employees.

The most recent close on file for INMB is $2.44, dated September 4, 2026. That is +$0.17 (+7.49%) against the previous close. Over the past 52 weeks the price has ranged from $1.09 to $2.50. The latest close sits 123.85% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $50.00K. Against the prior fiscal year total of $14.00K, that is a change of +257.14%. The same year closed with a net loss of $45.93M. The reported profit margin is 0%. Trailing earnings per share are −0.62.

Across the 4 fiscal years on file, revenue moves from $374.00K in 2022 to $50.00K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Beta against the wider market is reported at 0.94. Annualized volatility over the trailing 7 years is 94.2%. The trailing one-year price return is +27.08%. Across 5 years the annualized return works out at −37.90%.

Growth & Income

No dividend is on file for INMB.

The strongest complete calendar year on file is 2020 at +196.90%; the weakest is 2025 at −66.60%. Of the 6 complete calendar years on file, 2 finished higher. 2026 is still running; the price is +56.41% year to date.

Peer Comparison

INmune Bio Inc. (INMB) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
INmune Bio Inc. INMB $67.72M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. INmune Bio Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About INmune Bio Inc.

INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; GOSH; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Visit website →